Senior Advisers

Andy Rust is a highly experienced pharmaceutical executive with direct experience marketing and selling licensed drugs in the USand in the pain sector. Andy has also served as a senior commercial executiveof several international pharmaceutical companies over a 30-year career and hismost recent role was as Global Head of Respiratory with Chiesi Group, aninternational biopharmaceutical company which has a direct presence in 31countries. At Chiesi, Andy led the strategic direction and execution of thegroup’s respiratory portfolio, which included products for asthma and COPD, tosignificantly grow revenues for the company’s respiratory range to in excess of€1.5 billion. Andy will provide the Company with expert advice on its drugdevelopment and commercialisation plans.

‍

Chris was Chief Operating Officer of GW Pharmaceuticals plc for nearly 10 years, helping transition the company from a predominantly R&D company to a fully-fledged International commercial business followingregulatory approvals of its lead products – which were world-firsts in their space. Following the acquisition in 2021 of GW Pharma for $7.2bn by JazzPharmaceuticals, he became Chief Operating Officer and Managing Director of Europe & International until his departure from Jazz at the end of 2022. Subsequentlyfor 12 months he lead Destiny Pharma a clinical phase biotechnology company dedicated to infection prevention, as Chief Executive Officer. 

He has over 35 years of commercial leadership and operationsexperience including at GlaxoSmithKline and UCB where he was Vice President Head Of Global Marketing Operations.  Chris has worked across a widerange of geographies, functions and therapeutic areas including infectious diseases, neurology, oncology, diabetes, respiratory and immunology. Chris holds a BSc. degree in Marine Biology from the University of Liverpool.